Comparison Influence to Prognosis of CTP and MRP in AIS Patients

Recruiting Observational Study
Stroke
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
1,000 (estimated)
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Acute ischemia stroke (AIS) is the leading cause of death in China. Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) has been proven to reduce disability in AIS patients within 4.5 hours after symptom onset. However, only 2% of AIS patients received thrombolytic therapy in China. Perfusion imaging is demonstrated to increase the rate of thrombolytic therapy by identifyin…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Criteria: Inclusion Criteria: 1. Provision of informed consent; 2. Male and female adults aged 18-80 years old; 3. For patients accepting CTP or MRP over 4.5 hours after stroke onset, imaging criteria: infarct core volume \<70mL, perfusion leison volume / infarct core volume \>1.2, and absolute mi…
Contacts

Min Lou, Ph.D

13958007213

loumingxc@vip.sina.com

CONTACT